EXTENDED SPECTRUM Î²-LACTAMASE PRODUCING MULTIDRUG-RESISTANT KLEBSIELLA SPECIES ISOLATED AT NATIONAL MEDICAL COLLEGE AND TEACHING HOSPITAL, NEPAL
Introduction: Extended spectrum Î²- lactamases (ESBL) producing multidrug resistant (MDR) Klebsiella species resulting in limitation of therapeutic option. The present study has been undertaken to detect the presence of extended spectrum Î²- lactamases producing multidrug resistant Klebsiella species in various clinical specimens.
Methodology: A total of 300 specimens including Urine, Pus and Blood were processed according to the standard methodology. Antibiotic susceptibility testing was done by Kirby Bauer disc diffusion method following Clinical and Laboratory standard institute (CLSI) guidelines. Combination disk method was done for the detection of extended spectrum Î²- lactamases producing isolates.
Â Result: A total of 300 samples (200 urine, 45 bloods and 55 pus) were included in the study. Out of total samples proceed 110(36.7percent) samples showed significant growth of Gram-negative bacteria. Amongst these significant growth of 65(59.1percent) Klebsiella species, 45(69.2percent) Klebsiella pneumonia and 20(30.8percent) Klebsiella oxytoca were isolated. Amongst these total isolated Klebsiella species 30(66.7percent) multidrug resistant Klebsiella pneumonia and 9(45.0percent) multidrug resistant Klebsiella oxytoca were isolated. A total of 21(70.0percent) Klebsiella pneumonia isolates and 4(44.4percent) Klebsiella oxytoca isolates were found to be extended spectrum Î²- lactamases producers.
Conclusion: This study shows that Klebsiella pneumonia and Klebsiella oxytoca recovered from clinical specimens in this region produces extended spectrum Î²- lactamases in much higher number. Such isolates are also resistant to Floroquinolones, Aminoglycosides, Tetracycline and Cotrimoxazole. Further studies to investigate the factors which determine the emergence and persistence of multidrug resistant extended spectrum Î²- lactamases producing Klebsiella species in this region and their impact on clinical and economic outcomes at such institutions would be useful.
Keywords: Antibiotic susceptibility testing, MDR, ESBL, Combined disk assay,
2. Cryz SJ, Furer R, Germanier R. Protection against fatal Klebsiella pneumonia burn wound sepsis by passive transfer of anticapsuler polysaccharide. Infect. Immun.  45 : 139-142.
3. Wei H, Shen J, Pang X, Ding D, Zhang Y, Zhang B, Lu H, Wang T, Zhang C, Hua X, Cui L, Zha L. Fatal infection in human floraâ€“associated piglets caused by the opportunistic pathogen Klebsiella pneumonia from an apparently healthy human donar. J.Vet. Med. Sci.  70 :715-717. DOI P Mid: 18685245.
4. Yan JJ, Wen-Chien K, Shu-Huei T, Hsiu-Mei W, and Jiunn-Jong W. Outbreak of infection with Multi-drug-Resistant Klebsiella pneumoniae carrying blaIMP -8in a university medical centre in Taiwan. J. Clin. Microbial.  39 : 4433-4439. DOI PMCid: 88561.
5. Ktari S, Arlet G, Mnif B, Gautier V, Mahjoubi F, Jmeaa MB, Bouaziz, M, and Hammami, A. Emergence of Multidrug-Resistant Klebsiella pneumonia isolates producing VIM-4 Metallo-Î²- Lactamase, CTX-M-15 Extended spectrum Î²-Lactamase in a Tunisian University Hospital. Antimicrob. Agents. Chemother.  50 : 4198-4201. DOI PMid: 17015633 PMC-id: 1694011.
6. Marra AR, Wey SB, Castela A, Gales AC, Cal RG, Flha JR, Edmond MB, Perelra CA. Noscomial blood stream infection caused by Klebsiella pneumonia: impact of extended spectrum beta lactamases (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.BMC Infect Dis. [2006 ] 14 : 24.
7. Dean AD, Dean AJ, Burton AH, Dicker RC. Epi- Info version 5: a word processing database and statistics programme for epidemiology on microcomputers. VSD. Inc Stone Mountain Ga; 1990.
8. Arlet G, Rouvea M, Casin I, Bouvet PJM, Lagrange PH, Phillippon A. Molecular epidemiology of Klebsiella pneumonia strains that produce SHV-4 Î²- lactamase and which were isolated in 14 French hospitals. J.Clin. Microbiol  32 : 2553-2558.
9. Jacoby GA, Medeinos AA. More extended spectrum Î² lactamases. Antimicrob. Agents. Chemother.  35 : 1697-1704.
10. Jarlier V, Nicolas MH, Fournier GA. Philippon A. Extended broad spectrum Î² lactamases conferring transferable resistance to newer beta-lactamae, agents in enterobacteriaceae hospital prevalence and susceptibility patterns. Rev. Infect. Dis  10 : 867-878.
11. Verbist L. Incidence of multi resistance in gram-negative bacterial isolates from intensive care unit in Belgium- a surveillance study. Scand. J.Infect.Dis.Supp.  78: 45-53.
12. Blat S, Depudt P, Vandewoude K, Bacquer D De. Measuring the impact of multidrug resistance in noscomial infection. Curr opin infect Dis.  20 : 391-396, Review.
13. Bergey DH, John GH. Bergeyâ€™s manual of determinative biology. 9th ed. William and Wilkins; 1994.
14. Bauer AW, Kirby W, Sherris J, Turck M. Antibiotic susceptibility testing by a standard single disc method. Am J Clin Pathol.  45 : 493-6.
15. Clinical and Laboratory Standards Institute/NCCLS performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS M 100-S15. Clinical and Laboratory Standards institute, Wayne, Pa: 2005
16. Jain A, Ray I, Gupta,KM., Kumar M and Agarwal SK. Prevalence of extended spectrum Î²-lactamase producing Gram-negative bacteria in septicaemic neonates in tertiary care hospital. J.Med.Res.  52 :421-5.
17. Abigail S, Elizabeth M, Jesudason MV, John TJ. Ceftazidime resistance among Klebsiella pneumoniae in South India. Ind. J. Med. Res.  102:53-55.
18. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill.  13 : 19051.
19. Stobberingh, EE, Arends J, Kostanje J, Goessens A, Visser WHF, Buiting MR. Occurrence of extended spectrum Î²-lactamases in Dutch hospitals. Infection.  27: 348-354.
20. Xiong Z, Zhu D, Zhang Y. and Wang F. Extended spectrum Î²-lactamases in K. pneumoniae and E. coli isolates. Zhonghua Yi Xua Za Zhi  82: 1476-1479.
21. Shah RK, Singh YI, Sanjana RK, Chaudhary N, Saldanha D. Study of extended spectrum Î² lactamases (ESBLs) producing Klebsiella species in various clinical specimens. A preliminary report. Journal of college of medical sciences-Nepal  6:19-23.
22. Bradford PA. Extended-spectrum Î²-lactamases in the 21st century: characterization, epidemiology and detection of this important threat. Clin Microbiol Rev.  14: 933-51.
23. Nicholson AM, Gayle P, Roye-Green K. Extended spectrum beta-lactamase producing organisms at the University hospital of the West Indies. West Indian Med J  53 :104-8.
24. Kader AA, Kumar AK. Prevalence of extended spectrum beta-lactamase among multidrug resistant Gram negative bacterial isolates from a general hospital in Saudi Arabia. Saudi Med J  25 :570-4.
25. Agata DE, Venkataraman I, DeGirolami P, Weigel L, Samore M. and Tenover F. The molecular and clinical epidemiology of Enterobacteriaceae producing extended spectrum beta lactamase in a tertiary care hospital. Journal of Infectious Diseases  36 : 279-285.
26. Muratani T, MatsumotoT. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Intern. J. Antimicrob. Agent  28 : S10â€“S13.
27. Bashir MF, Qazi JI, Ahmad N, Riaz S. Diversity of Urinary Tract Pathogens and Drug Resistant Isolates of Escherichia coli in different age and gender Groups of Pakistanis. Trop. J. Pharm. Res.  7 : 1025-1031.
28. Aktas E, Yigit N. Detection of antimicrobial resistance and extended-spectrum beta-lactamase production in Klebsiella pneumoniae strains from infected neonates. J. Int. Med. Res. 30 : 445-8.
29. Jett BD, Ritchie DJ. In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob.Agents Chemother.  39 : 1187-90.
30. Ullah,F, Malik AS and Ahmed J. Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the North-West of Pakistan. Afr J Microbiol Res.  3  676-680.
31. Singh NP, Goyal R, Manchanda V, Das S, Kaur I, Talwar V. Changing trends in bacteriology of burns in the burns unit, Delhi, India. Burns.  29 : 129-32.
32. Panta K, Ghimire P, Rai SK, Mukhiya RK, Singh RN, Rai G. Antibiogram typing of gram negative isolates in different clinical samples of a tertiary hospital. Asian J Pharm Clin Res.  6 :153-156
33. Gonzalez LS, Spencer JP. Aminoglycosides: a practical review. Am. Fam. Physician.  58 : 1811-20.
34. Ahmed A, Lutfi S, Hail M, Sadia M. Antibiotic susceptibility patterns of microbial isolates from blood culture in the neonatal intensive care unit of hamad medical corporation (hmc), Doha, Qatar. Asian J Pharm Clin Res.  6 : 191-195
35. Revathi G, Puri J. Bacteriology of burns. Burns. 24 : 347-9.
36. Miller GH, Sabatelli FJ. The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin. Infect. Dis. Suppl.  24 : S46-62.
37. Fedler KA, Biedenbach DJ. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the  SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn. Microbiol. Infect. Dis.  56 : 427-36.
38. Digranes A, Solberg CO .Susceptibility of 4410 clinical isolates to doxycycline. Scand. J. Gastroenterol. Suppl.  59: 3-4.
39. Bauernfeind A, Horl G. Microbiological perspectives of cotrimoxazole. Infect. Suppl.  15 : S232-5.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.